A conservative, pro-business president who campaigned on reducing taxes, reducing regulations, improving U.S. trade policies and creating jobs. Sounds great for the life science industry. Right?
Not so fast.
At his January 31, 2017 meeting with pharmaceutical industry leaders, reviews were mixed. Right out of the gate, president Trump decreed the following: